OmniAb, Inc. (NASDAQ: OABI) reported an insider transaction by Chief Legal Officer Charles S. Berkman on April 7, 2026. On that date, Berkman sold 7,157 shares of common stock at prices between $1.46 and $1.53, yielding total proceeds of $10,663.
Also on April 7, Berkman exercised options to acquire 13,542 shares of common stock at an exercise price of $0. The acquisition stemmed from the vesting of restricted stock units. After completing both the sale and the option exercise, Berkman is shown as directly owning 399,085 shares of OmniAb.
The insider activity took place while OmniAb shares were trading at $1.51. The stock has declined 18% year-to-date and is down nearly 21% over the past 12 months. An InvestingPro analysis included in public reporting indicates the stock appears slightly overvalued relative to its Fair Value estimate. Investors seeking expanded commentary can consult InvestingPro's Pro Research Report, one of more than 1,400 reports available with further analysis and data on U.S. equities.
OmniAb's most recent financial disclosures covered fourth-quarter fiscal 2025 results. The company reported revenue of $8.4 million for the quarter, down from $10.8 million in the same period a year earlier. OmniAb recorded a net loss of $14.2 million for the quarter, equivalent to a loss of $0.11 per share, compared with a loss of $0.12 per share in the fourth quarter of fiscal 2024.
Following the earnings release, a number of brokerages reiterated positive stances on the company. Benchmark maintained a Buy rating and a $4.00 price target. Stifel preserved its Buy rating, citing a 17% increase in active partners and a 12% rise in programs year-over-year as indicators of partnership growth.
Truist Securities also reaffirmed a Buy rating, noting recent favorable developments in the biotech sector that could support OmniAb's current initiatives. Truist referenced the company’s 32 partner programs that are in trials or commercialization as potentially benefiting from broader sector momentum.
Leerink Partners reiterated an Outperform rating with a $10.00 price target, stating that the failure of Immunovant's Phase 3 trial for batoclimab in thyroid eye disease does not alter OmniAb's outlook. According to Leerink, Immunovant has redirected its clinical development focus toward IMVT-1402, a shift the firm considered positive.
Taken together, the broker commentary reflects continued confidence among several analysts in OmniAb's prospects despite the recent revenue decline and quarterly loss. The combination of insider transactions, current stock performance, and reiterated analyst ratings frames the near-term narrative for the company in public markets.
Is OABI a bargain right now? For investors who want a valuation perspective, a Fair Value calculator is available that uses a mix of 17 proven industry valuation models. The tool is presented as a way to compare a stock's market price with estimated intrinsic value and is applied across thousands of equities to help identify potential investment opportunities.